title: The impact of cyclosporine on the development of immunosuppressive therapy for pediatric liver transplantation.
abstract: Since the introduction of cyclosporine into pediatric liver transplantation remarkable progress in patient and graft survival has been observed: survival rates 60%; acute (60%), steroid-resistant (22%) and chronic rejection (4%); infections (60%); and side effects (20%). Individualization of cyclosporine therapy complements the development of new immunosuppressive agents such as tacrolimus, mycophenolate mofetil, and sirolimus for specific indications. The ultimate goal of transplantation to achieve immunotolerance a waits future progress.
authors.affiliation: Universitätsklinikum Hamburg-Eppendorf, Department of Pediatrics, Hamburg, Germany. burdelsk@uke.uni-hamburg.de
authors.forename: M M
authors.initials: MM
authors.lastname: Burdelski
mesh_terms: D000208:Acute Disease; D002648:Child; D002908:Chronic Disease; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000276:immunology* / Q000401:mortality; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine